[
  {
    "ts": "2026-01-08T14:03:38+00:00",
    "headline": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
    "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
    "url": "https://finance.yahoo.com/news/merck-upgraded-post-keytruda-growth-140338938.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "458fcfd3-f421-3f31-bce7-a992a25749af",
      "content": {
        "id": "458fcfd3-f421-3f31-bce7-a992a25749af",
        "contentType": "STORY",
        "title": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
        "description": "",
        "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
        "pubDate": "2026-01-08T14:03:38Z",
        "displayTime": "2026-01-08T14:03:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-upgraded-post-keytruda-growth-140338938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-upgraded-post-keytruda-growth-140338938.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T08:00:00+00:00",
    "headline": "Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?",
    "summary": "The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.",
    "url": "https://www.pharmavoice.com/news/billionaire-sean-parker-cancer-research-development-drug-pharma/809076/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "1699b328-2bfe-3236-b695-8ef97117e7b6",
      "content": {
        "id": "1699b328-2bfe-3236-b695-8ef97117e7b6",
        "contentType": "STORY",
        "title": "Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?",
        "description": "",
        "summary": "The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.",
        "pubDate": "2026-01-08T08:00:00Z",
        "displayTime": "2026-01-08T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/3689c2c92de77aa5858857359e17cd44",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Entrepreneur and philanthropis Sean Parker.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c0m7DUvyIyGQvMgIP4GhPQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/3689c2c92de77aa5858857359e17cd44.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vi12vdxt2tZ4AP9Cpsjf0A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/3689c2c92de77aa5858857359e17cd44.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/billionaire-sean-parker-cancer-research-development-drug-pharma/809076/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/billionaire-sean-parker-already-shaken-080000359.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T14:45:03+00:00",
    "headline": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144503453.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "40ccc5c3-864b-3b0d-a2da-6cd39d1b8553",
      "content": {
        "id": "40ccc5c3-864b-3b0d-a2da-6cd39d1b8553",
        "contentType": "STORY",
        "title": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2026-01-08T14:45:03Z",
        "displayTime": "2026-01-08T14:45:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9.bMA28djqdXWkJ0xgkrvA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yGQaN1QLRXutAaqBqcTUKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144503453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144503453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T21:27:50+00:00",
    "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines",
    "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn, in...",
    "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "c02e1d7d-86f0-3c3d-833e-0f605758d4c5",
      "content": {
        "id": "c02e1d7d-86f0-3c3d-833e-0f605758d4c5",
        "contentType": "STORY",
        "title": "Merck in talks to buy cancer drugmaker Revolution Medicines",
        "description": "",
        "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn, in...",
        "pubDate": "2026-01-08T21:27:50Z",
        "displayTime": "2026-01-08T21:36:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca",
          "originalWidth": 4950,
          "originalHeight": 3144,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rbgNX1ePcKwZLzZG16B47w--~B/aD0zMTQ0O3c9NDk1MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca.cf.webp",
              "width": 4950,
              "height": 3144,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RfLWNvSS9QOylx4dVziNeQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2023-06/9eb18570-046b-11ee-abfa-6008b1e541ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-cancer-drugmaker-212750083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T21:25:34+00:00",
    "headline": "Revolution Medicines stock rises on Merck acquisition talks",
    "summary": "Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock rose 5% Thursday following a Financial Times report that Merck (NYSE:MRK) is in talks to acquire the biotech company.",
    "url": "https://finance.yahoo.com/news/revolution-medicines-stock-rises-merck-212534338.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "b0981830-06fa-3ecc-9c95-1fd9d9d75f2d",
      "content": {
        "id": "b0981830-06fa-3ecc-9c95-1fd9d9d75f2d",
        "contentType": "STORY",
        "title": "Revolution Medicines stock rises on Merck acquisition talks",
        "description": "",
        "summary": "Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock rose 5% Thursday following a Financial Times report that Merck (NYSE:MRK) is in talks to acquire the biotech company.",
        "pubDate": "2026-01-08T21:25:34Z",
        "displayTime": "2026-01-08T21:25:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-stock-rises-merck-212534338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-stock-rises-merck-212534338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T21:14:00+00:00",
    "headline": "GenNx360 Capital Partners Portfolio Company Nutra-Med Packaging Appoints Hany Salama as Chief Executive Officer",
    "summary": "NEW YORK, January 08, 2026--GenNx360 Capital Partners (\"GenNx360\"), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging (\"Nutra-Med\" or the \"Company\"), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effe",
    "url": "https://finance.yahoo.com/news/gennx360-capital-partners-portfolio-company-211400917.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "81281fcd-efb8-3c6e-b4e1-6f059c1f229d",
      "content": {
        "id": "81281fcd-efb8-3c6e-b4e1-6f059c1f229d",
        "contentType": "STORY",
        "title": "GenNx360 Capital Partners Portfolio Company Nutra-Med Packaging Appoints Hany Salama as Chief Executive Officer",
        "description": "",
        "summary": "NEW YORK, January 08, 2026--GenNx360 Capital Partners (\"GenNx360\"), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging (\"Nutra-Med\" or the \"Company\"), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effe",
        "pubDate": "2026-01-08T21:14:00Z",
        "displayTime": "2026-01-08T21:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/b54aa9c1f0f87103758095dd90bca7fe",
          "originalWidth": 480,
          "originalHeight": 435,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9gXRL4WP1IT67CMrV6bYNg--~B/aD00MzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b54aa9c1f0f87103758095dd90bca7fe.cf.webp",
              "width": 480,
              "height": 435,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pTMR9uanHF17oNyughxANg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b54aa9c1f0f87103758095dd90bca7fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gennx360-capital-partners-portfolio-company-211400917.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gennx360-capital-partners-portfolio-company-211400917.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "BASFY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T20:58:28+00:00",
    "headline": "Merck in talks to buy biotech Revolution Medicines, FT reports",
    "summary": "Jan 8 () - Merck is in talks to ​buy cancer drug developer ‌Revolution Medicines, the Financial Times ‌reported on Thursday, citing people familiar with the matter. Shares of Revolution were ⁠up 5.",
    "url": "https://finance.yahoo.com/news/merck-talks-buy-biotech-revolution-205828159.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "1987ab31-8bb7-33aa-a80e-068da282c1c0",
      "content": {
        "id": "1987ab31-8bb7-33aa-a80e-068da282c1c0",
        "contentType": "STORY",
        "title": "Merck in talks to buy biotech Revolution Medicines, FT reports",
        "description": "",
        "summary": "Jan 8 () - Merck is in talks to ​buy cancer drug developer ‌Revolution Medicines, the Financial Times ‌reported on Thursday, citing people familiar with the matter. Shares of Revolution were ⁠up 5.",
        "pubDate": "2026-01-08T20:58:28Z",
        "displayTime": "2026-01-08T20:58:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/9864f423d03771cceaa5732217377e7e",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "FILE PHOTO: Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KcNTvzg87oheL9YHu.xQ.A--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/9864f423d03771cceaa5732217377e7e.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MTePt1wYxvK0P8pKeqNBtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/9864f423d03771cceaa5732217377e7e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-biotech-revolution-205828159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-talks-buy-biotech-revolution-205828159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T22:56:45+00:00",
    "headline": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead Split Market",
    "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-small-caps-jobs-data-trump-tariffs-ruling/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2a3d656e-215b-3c5a-8913-f46b10c1962e",
      "content": {
        "id": "2a3d656e-215b-3c5a-8913-f46b10c1962e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead Split Market",
        "description": "",
        "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
        "pubDate": "2026-01-08T22:56:45Z",
        "displayTime": "2026-01-08T22:56:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2a3d656e-215b-3c5a-8913-f46b10c1962e/dow-jones-futures-jobs-data-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/64ef26e69822a4e4837c82dd3425fad5",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a7cU.xPWSHpzasiZQqNSKQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/64ef26e69822a4e4837c82dd3425fad5.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vd.TiGl0aqSn9so9Pgd.5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/64ef26e69822a4e4837c82dd3425fad5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-small-caps-jobs-data-trump-tariffs-ruling/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "TSM"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "VLO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]